{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:07:32Z","timestamp":1792710452077,"version":"4.5.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have brought impressive benefits to cancer patients, however often accompanied with immune-related adverse events (irAEs). We aimed to investigate the association of irAEs with efficacy and overall survival in cancer patients treated by ICIs, and further quantify the association by stratifying subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE and Cochrane library from database inception to 29 August 2019 were systematically searched. Articles reporting association of objective response rate (ORR), progression-free survival (PFS), overall survival (OS) with irAEs in cancer patients treated with approved ICIs were included. Adjusted odds ratios (OR) with 95% confidential intervals (CIs) were calculated for ORR, and hazard ratios (HR) were used for PFS and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 52 articles comprising 9,156 patients were included. Pooled data demonstrated a statistically significant greater probability of achieving objective tumor response for patients with irAEs compared to those without (OR 3.91, 95% CI 3.05\u20135.02). In overall meta-analysis, patients who developed irAEs presented a prolonged PFS (HR 0.54; 95% CI 0.46\u20130.62) and OS (HR 0.51; 95% CI 0.41\u20130.59). More specifically, irAEs in certain cancer types (NSCLC and melanoma) and organs (skin and endocrine) were robustly associated with better clinical outcomes, while this association needs further verification regarding other tumors. High grade toxicities (G3\u20135) were not associated with a significantly favorable PFS or OS. Additionally, the association between irAEs and clinical benefit seemed to be more definite in patients receiving PD-(L)1 blockade than CTLA-4 blockade. Pooled data from landmark analyses displayed consistent results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The occurrence of irAEs predicted improved tumor response and better survival in overall cancer patients treated with ICIs. Notably, the association stayed robust in certain cancer types (NSCLC and melanoma) and organ-specific irAEs (skin and endocrine).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2021.633032","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T02:02:00Z","timestamp":1618192920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":120,"title":["Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Yong","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20181003","article-title":"Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers","volume":"133","author":"Inthagard","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s40425-018-0477-9","article-title":"Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182395","article-title":"Development of immune checkpoint therapy for cancer","volume":"216","author":"Fritz","year":"2019","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11684-019-0735-3","article-title":"Advances on immune-related adverse events associated with immune checkpoint inhibitors","volume":"15","author":"Fan","year":"2021","journal-title":"Front Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1479-5876-12-116","article-title":"Clinical experience with ipilimumab 3 mg\/kg: real-world efficacy and safety data from an expanded access programme cohort","volume":"12","author":"Ascierto","year":"2014","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0083","article-title":"Use of LDH and autoimmune side effects to predict response to ipilimumab treatment","volume":"8","author":"Dick","year":"2016","journal-title":"Immunotherapy"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer","volume":"5","author":"Hasan Ali","year":"2016","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13241","article-title":"Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2018.02.017","article-title":"Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study","volume":"119","author":"Fujimoto","year":"2018","journal-title":"Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.10.009","article-title":"Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients","volume":"89","author":"Fujisawa","year":"2018","journal-title":"J Dermatol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1825","article-title":"Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC","volume":"7","author":"Lesueur","year":"2018","journal-title":"Cancer Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.07.003","article-title":"Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1\/PD-L1 therapy","volume":"45","author":"Shafqat","year":"2018","journal-title":"Semin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2092-x","article-title":"Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody","volume":"67","author":"Suh","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02899-y","article-title":"Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice","volume":"145","author":"Ahn","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1615636","article-title":"Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study","volume":"58","author":"Bjornhart","year":"2019","journal-title":"Acta Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"355 e21","DOI":"10.1016\/j.urolonc.2019.03.003","article-title":"Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"37","author":"Ishihara","year":"2019","journal-title":"Urol Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.cllc.2018.09.005","article-title":"Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis","volume":"20","author":"Ksienski","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0146","article-title":"Clinical significance of signs of autoimmune colitis in (18)F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients","volume":"11","author":"Lang","year":"2019","journal-title":"Immunotherapy"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219829813","article-title":"Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors","volume":"25","author":"Lei","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","article-title":"Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study","volume":"41","author":"Okada","year":"2019","journal-title":"Clin Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/00016489.2019.1648867","article-title":"Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study","volume":"139","author":"Okamoto","year":"2019","journal-title":"Acta Oto-Laryngol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10466","article-title":"Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade","volume":"18","author":"Sakakida","year":"2019","journal-title":"Oncol Lett"},{"key":"B65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PloS One"},{"key":"B67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.03.059","article-title":"Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival","volume":"152","author":"Soneji","year":"2017","journal-title":"Chest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181b27b15","article-title":"Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status","volume":"4","author":"Ou","year":"2009","journal-title":"J Thorac Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23181","article-title":"Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting","volume":"9","author":"Petrizzo","year":"2018","journal-title":"Oncotarget"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.633032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T02:02:03Z","timestamp":1618192923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.633032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":76,"alternative-id":["10.3389\/fonc.2021.633032"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.633032","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"article-number":"633032"}}